Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBITDA (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of EBITDA data on record, last reported at -$18.1 million in Q3 2025.

  • For Q3 2025, EBITDA rose 37.21% year-over-year to -$18.1 million; the TTM value through Sep 2025 reached -$47.6 million, up 32.89%, while the annual FY2024 figure was -$52.8 million, 25.71% up from the prior year.
  • EBITDA reached -$18.1 million in Q3 2025 per SNTI's latest filing, down from -$14.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1178.0 in Q1 2021 and bottomed at -$28.9 million in Q3 2024.
  • Average EBITDA over 5 years is -$13.2 million, with a median of -$14.1 million recorded in 2025.
  • Peak YoY movement for EBITDA: tumbled 1002276.91% in 2022, then soared 96.74% in 2024.
  • A 5-year view of EBITDA shows it stood at -$10.9 million in 2021, then tumbled by 66.99% to -$18.2 million in 2022, then fell by 2.78% to -$18.7 million in 2023, then skyrocketed by 96.74% to -$610000.0 in 2024, then crashed by 2871.48% to -$18.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$18.1 million in Q3 2025, -$14.7 million in Q2 2025, and -$14.1 million in Q1 2025.